Cooperative Agreement R43CA221473

This $683,472 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Cincinnati to develop a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to therapeutically target the DHODH enzyme to induce AML cell differentiation, activate the immune system, and induce ferroptosis-mediated cell death. This approach aims to better differentiate AML cells from normal hematopoietic stem cells and enhance...

This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...

The National Cancer Institute (NCI) awarded a $483,110 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Beckman Research Institute of the City of Hope to conduct research on the functional role of PAX5 mutations in B-cell acute lymphoblastic leukemia (B-ALL). The 5-year project aims to systematically dissect the mechanisms by which PAX5 mutations, which occur in over 10% of B-ALL cases, contribute to disease initiation and progression. The research will use orthogonal...

The National Cancer Institute awarded a $966,220 Project Grant to Beckman Research Institute of the City of Hope under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025, through August 31, 2030. This five-year research initiative focuses on dissecting the functional role of PAX5 mutations in B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer. The project will deliver fundamental research findings on PAX5-driven B-ALL subtypes (PAX5ALT and...

Sanicka, Inc. was awarded a $793,816 Project Grant from the National Cancer Institute, a component of the Department of Health and Human Services, to develop precision medicine tools for optimizing personalized treatment of patients with acute myeloid leukemia. Under the grant, Sanicka will launch a clinical decision support service called PCITTM Simulator to assist oncologists in simulating disease response and progression for AML patients receiving various chemotherapy, small molecule...

This $878,400 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research characterizing vitamin B6 pathway dependency in acute myeloid leukemia (AML) at Cold Spring Harbor Laboratory from January 2023 through December 2027. The research aims to further the understanding of the underlying mechanisms of AML by studying abnormal vitamin pathways and metabolic programming...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a targeted therapy for acute myeloid leukemia (AML) with the chromosome inversion inv(16). The $545,170 award to Versiti Wisconsin, Inc. aims to characterize the mechanisms by which the oncogenic fusion protein CBFB-SMMHC activates the translation initiation factor EIF4G1, leading to AML transformation. The research will test whether inhibiting EIF4G1 can overcome...

This Project Grant award of $502,516 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Case Western Reserve University focused on developing a small-molecule degrader called SISU-102 to target leukemic stem cells (LSCs) in acute myeloid leukemia (AML). The key objectives are to further investigate the impacts of these HSF1 degraders on LSC self-renewal, identify sensitive and resistant AML subtypes, and explore the underlying mechanisms. This...

This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...

Federal Grant Award Summary The National Cancer Institute awarded Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research deliverables include characterization of A978's biological effects in leukemic...